报价延迟最少15分钟:2025/09/05 17:04 EDT
盘后时段
|
||||
|
9.9 
|
|
|
常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
9.86
|
|
|
| 价值评估 |
|
盈利(现时/预测)
-4.76/-5.93
|
|
企业价值
124.43M
|
| 资产负债 |
|
每股账面净值
9.06
|
| 现金流量 |
|
现金流量率
--
|
| 损益表 |
|
收益
0
|
|
每股收益
--
|
|
同行比较
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
报价延迟最少15分钟：2025/09/05 17:04 EDT
同行比较之报价最少15分钟延迟
|
业务概览
|
|||
| Corbus Pharmaceuticals Holdings Inc is a precision oncology company with a diversified portfolio and is committed to helping people defeat serious illness by bringing scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity. |
